Anemia during pregnancy is a significant global health challenge, affecting approximately 37% of pregnant women worldwide. In sub-Saharan Africa, this burden is even greater, with nearly 50% of expectant mothers experiencing this condition. The consequences of anemia are severe, ranging from increased maternal mortality to adverse neonatal outcomes such as low birth weight and preterm delivery. Traditionally, oral iron supplements have been used to address iron deficiency, the leading cause of anemia in pregnancy, but new research suggests that intravenous (IV) iron infusions, particularly ferric carboxymaltose (FCM), could offer a more effective solution in late pregnancy.
The Challenges of Oral Iron Supplementation
The World Health Organization (WHO) has long recommended daily oral iron supplements to combat iron deficiency in pregnant women. However, adherence to this regimen remains low, especially in low-resource settings. In sub-Saharan Africa, for example, only 29% of pregnant women complete the prescribed course of oral iron. This poor adherence is due to several factors, including side effects such as nausea and constipation, and the difficulty of ensuring that women take the supplements consistently.
The ineffectiveness of oral iron supplementation becomes particularly problematic in late pregnancy when the need for iron increases, but there is insufficient time for oral iron to adequately restore hemoglobin levels before labor. This delay in correcting anemia leaves women vulnerable to complications such as chronic fatigue and postpartum hemorrhage, both of which contribute to maternal morbidity and mortality.
The Potential of Intravenous Iron Infusions
To overcome the limitations of oral iron, intravenous iron formulations like ferric carboxymaltose (FCM) offer a promising alternative. FCM can be administered in a single infusion, providing up to 1,000 mg of iron quickly. This method allows for a more reliable and faster correction of iron deficiency, which can be particularly beneficial in the third trimester of pregnancy.
Research Findings: FCM vs. Oral Iron
A groundbreaking study conducted by researchers from WEHI (Australia) and the Training Research Unit of Excellence in Malawi aimed to assess the efficacy of FCM compared to oral iron in treating moderate to severe anemia during the third trimester of pregnancy. This study involved 590 pregnant women in southern Malawi and is one of the largest trials of its kind.
The women were randomly assigned to receive either a single FCM infusion or a standard regimen of oral iron tablets. The trial followed the women through delivery and up to four weeks postpartum.
The results were notable:
- 46.7% of women in the FCM group were still anemic at the time of delivery.
- 62.7% of women in the oral iron group remained anemic at delivery.
This significant reduction in anemia prevalence among women who received FCM highlights the potential of intravenous iron infusions to improve maternal health outcomes, particularly in addressing anemia in late pregnancy.
Addressing the Challenges in Low-Resource Settings
One of the key takeaways from this study is the challenge of identifying and treating anemia in low-resource settings. In Malawi, many women do not access antenatal care until late in their pregnancies, which limits the opportunity for early intervention with iron supplementation. The study underscores the need for improved access to antenatal care and more efficient treatment methods like intravenous iron to prevent complications related to anemia in pregnancy.
Related topics:
Why Do Submucosal Fibroids Cause Heavy Bleeding?
